COMMUNIQUÉS West-GlobeNewswire

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
31/05/2024
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, [...]
Immuron Board Changes
31/05/2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his [...]
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results
31/05/2024
LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as [...]
Immuron CEO Steven Lydeamore to present at Peak Sky High
31/05/2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer [...]
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
31/05/2024
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 th [...]
Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié
31/05/2024
Sanofi lance son plan mondial 2024 d’actionnariat salarié Paris, le 31 mai 2024. Sanofi lance Action 2024, son plan mondial d’actionnariat salarié, qui sera ouvert le 4 juin 2024 à environ 80 000 salariés dans 56 pays. [...]
Merus annonce la fixation du prix de l’offre publique d’actions ordinaires élargie
31/05/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 31 mai 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre/nos »), une société d’oncologie au stade clinique qui développe [...]
Trading by management and close relations of management
31/05/2024
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares
31/05/2024
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA ( [...]
Nyxoah Annonce la Clôture de l’Offre et l’Exercice Partiel de l’Option d’Achat d’Actions Supplémentaires
31/05/2024
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Clôture de l’Offre et l’Exercice Partiel de l’Option d’Achat d’Actions Supplémentaires Mont-Saint-Guibert, Belgique – 31 mai 2024, 8h00 CET / 2h00 ET [...]
Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en cours
31/05/2024
Communiqué de presse Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en cours 31 mai 2024 – diffusion à 07h30 Sophia Antipolis [...]
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31/05/2024
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If [...]
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
31/05/2024
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating [...]
Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO
31/05/2024
Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO Recommandation pour les adultes atteints d’une BPCO non contrôlée avec éosinophilie sanguine élevée, basée sur les [...]
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
31/05/2024
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target [...]
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
31/05/2024
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
31/05/2024
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof. Krzysztof Narkiewicz, [...]
BioSenic S.A. : Information on the total number of voting rights and shares
31/05/2024
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 31, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and [...]
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
31/05/2024
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 31 mai 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]

Pages